Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions

Immuno-Oncology Scientific Symposium

Laboratory Considerations for Immuno-Oncology and Companion Diagnostics Development

Boston Marriott Cambridge, Cambridge, MA | November 15, 2018 - November 15, 2018 | 13:00 - 16:30 Add to Calendar
Register Now

About This Event

Join our Chief Scientific Officer, Patrice Hugo, Ph.D., and our team of scientific advisors as they discuss laboratory services solutions for Immuno-Oncology drug and companion diagnostic development. This scientific symposium, located at the Boston Marriott Cambridge hotel, will cover current topics and issues around immuno-oncology, and will include an integrated session between a panel of experts and the audience.

Agenda Outline
  • Laboratory Considerations for Immuno-Oncology and Companion Diagnostics Development
  • Anatomic Pathology for Developing Biomarkers and Companion Diagnostics for Immuno-Oncology Therapeutics
  • Gene expression for keeping pace with Immuno-Oncology breakthroughs and biomarker identification
  • Next Generation Flow Cytometry in Support of Immuno-Oncology
  • Companion and Complementary Diagnostics Partnerships
  • Immunogenicity and large molecule PK testing needs to support Immuno-Oncology trials
Check back here for final agenda.

Limited space available. Register now to secure your attendance.

Interested in being part of a panel discussion? Contact us here.


Patrice Hugo, Ph.D.
Immunology; Chief Scientific Officer

Dr. Hugo brings more than 25 years of senior scientific leadership experience with extensive management expertise in laboratory operations applied to diagnostics, therapeutic targets and clinical trials. Most recently, Dr. Hugo was Associate Vice President and Chief Scientist at LabCorp/Covance. He has held several other senior leadership positions at companies including Clearstone Central Laboratories, Caprion and PROCREA BioSciences. A noted industry expert, Dr. Hugo has more than 75 scientific publications in internationally renowned journals. He also is active in a number of industry organizations, including his role on the Board of Directors for the non-for-profit Personalized Medicine Partnership for Cancer in Quebec, Warnex, offering analytical and bioanalytical services and his role as a Steering Committee Member for the Biomarker Factory.

Dr. Hugo obtained his Ph.D. at McGill University and completed five years of post- doctoral fellowship at the Walter Elisa Hall Institute in Australia, and Howard Hughes Medical Institute in Denver, Colorado.

Updated as of September 2018.